Patients and Treatment Exposure
DISEASE PROGRESSION, DISEASE CHARACTERISTIC, -20
Between June 19, 2020, and the data cutoff date of January 31, 2022, there were 157 patients who were enrolled at 54 global sites and treated with epcoritamab. At a median follow-up of 10.7 months, 106 patients discontinued study treatment: 83 (52.9%) because of disease progression, 11 (7.0%) because of AEs, seven (4.5%) because of decision to undergo allogeneic transplantation, four (2.5%) because of patient withdrawal, and one (0.6%) after achieving a PR to undergo CAR T-cell therapy. Demographic and baseline disease characteristics are given in Table Demographic and Clinical Characteristics at Baseline in Patients With LBCLPatients received a median of five cycles (15 doses) of epcoritamab therapy (range, 1-20). As of the data cutoff date, 51 patients (32.5%) continued receiving study treatment; 56.1% continued into the follow-up period.